- Home
- HRMY vs PAX Comparison
HRMY vs PAX Comparison
Compare HRMY & PAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- PAX
- Stock Information
- Founded
- HRMY 2017
- PAX 1988
- Country
- HRMY United States
- PAX Cayman Islands
- Employees
- HRMY N/A
- PAX N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- PAX Investment Managers
- Sector
- HRMY Health Care
- PAX Finance
- Exchange
- HRMY Nasdaq
- PAX Nasdaq
- Market Cap
- HRMY 1.8B
- PAX 2.2B
- IPO Year
- HRMY 2020
- PAX 2021
- Fundamental
- Price
- HRMY $34.00
- PAX $13.70
- Analyst Decision
- HRMY Strong Buy
- PAX Strong Buy
- Analyst Count
- HRMY 9
- PAX 1
- Target Price
- HRMY $54.44
- PAX $14.00
- AVG Volume (30 Days)
- HRMY 642.5K
- PAX 503.7K
- Earning Date
- HRMY 08-05-2025
- PAX 08-01-2025
- Dividend Yield
- HRMY N/A
- PAX 6.40%
- EPS Growth
- HRMY 13.13
- PAX N/A
- EPS
- HRMY 2.62
- PAX 0.45
- Revenue
- HRMY $744,852,000.00
- PAX $389,900,000.00
- Revenue This Year
- HRMY $20.10
- PAX $5.53
- Revenue Next Year
- HRMY $18.01
- PAX N/A
- P/E Ratio
- HRMY $13.10
- PAX $30.16
- Revenue Growth
- HRMY 20.62
- PAX 22.70
- 52 Week Low
- HRMY $26.47
- PAX $9.43
- 52 Week High
- HRMY $41.61
- PAX $14.52
- Technical
- Relative Strength Index (RSI)
- HRMY 58.91
- PAX 50.56
- Support Level
- HRMY $31.70
- PAX $13.60
- Resistance Level
- HRMY $35.08
- PAX $14.52
- Average True Range (ATR)
- HRMY 0.95
- PAX 0.26
- MACD
- HRMY 0.27
- PAX -0.09
- Stochastic Oscillator
- HRMY 71.80
- PAX 18.00
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About PAX Patria Investments Limited
Patria Investments Ltd is an alternative asset management firm specializing in resilient sectors across select regions. It seeks to provide world-wide and Latin American investors with attractive investment products that allows portfolio diversification and consistent returns. The group promotes inclusive and sustainable development in the Asset Classes: Private Equity, Private Equity Solutions, Credit, Real Estate, Infrastructure, and Public Equities Main sectors: Agribusiness, Power & Energy, Healthcare, Logistics & Transportations, Food & Beverage and Digital & Tech Services Investment Regions.